Tailored Strategies for Evaluating Hypertension-Mediated Organ Damage

Overview

Hypertension-mediated organ damage (HMOD) significantly increases cardiovascular risk and is influenced by multiple patient-specific factors. Current major hypertension guidelines recommend basic HMOD assessment in all hypertensive patients, with advanced testing reserved for selected cases to optimize management.

Background

Chronic arterial hypertension causes structural and functional damage to organs including the heart, kidneys, brain, and eyes, collectively termed HMOD. The presence of HMOD is associated with a 2–3-fold increased risk of cardiovascular disease (CVD). Guidelines from major societies emphasize the importance of detecting HMOD to identify high-risk patients and guide treatment decisions. However, selecting appropriate diagnostic tools tailored to individual patient risk profiles remains a clinical challenge.

Data Highlights

Basic HMOD assessment includes electrocardiography, serum creatinine with estimated glomerular filtration rate (eGFR), and urinary albumin-creatinine ratio (UACR) in all hypertensive patients. Advanced testing such as echocardiography, arterial stiffness measurement, and imaging (e.g., coronary artery calcium scoring) is recommended selectively based on initial findings and likelihood to influence management.

Key Findings

• Basic screening for cardiac and renal HMOD is recommended for all patients with hypertension.
• Electrocardiography, serum creatinine, eGFR, and UACR are essential initial tests.
• Echocardiography is the preferred advanced test to assess cardiac involvement and provide prognostic information.
• Advanced assessments like arterial stiffness measurement and coronary artery calcium scoring are indicated in younger or borderline hypertensive patients when results may alter treatment.
• HMOD detection upgrades cardiovascular risk classification and may prompt earlier initiation of antihypertensive therapy.
• Guideline recommendations emphasize individualized testing strategies based on patient risk factors, comorbidities, and resource availability.

Clinical Implications

Clinicians should perform basic HMOD screening in all hypertensive patients to identify those at high cardiovascular risk. Advanced diagnostic modalities should be reserved for selected patients where findings will impact clinical management, ensuring efficient use of resources. Integrating HMOD assessment into routine care facilitates personalized risk stratification and treatment optimization.

Conclusion

Assessment of hypertension-mediated organ damage is critical for cardiovascular risk stratification and management. A tailored approach combining basic and advanced diagnostics based on individual patient characteristics and guideline recommendations optimizes care.

References

1. 2024 ESC, 2023 ESH, 2025 AHA/ACC, 2020 ISH Guidelines -- Hypertension-Mediated Organ Damage Assessment